When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. PARP inhibitor - Wikipedia

   en.wikipedia.org/wiki/PARP_inhibitor

   Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II: Olaparib (developed by AstraZeneca) for breast, ovarian and colorectal cancer. [33] [34] Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015). [35]

3. Olaparib - Wikipedia

   en.wikipedia.org/wiki/Olaparib

   In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...

4. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]

5. Gleason grading system - Wikipedia

   en.wikipedia.org/wiki/Gleason_grading_system

   The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic ...

6. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Prostate cancer is a major topic of ongoing research. From 2016 to 2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [122] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost ...

7. Rucaparib - Wikipedia

   en.wikipedia.org/wiki/Rucaparib

   Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture." [6] As a PARP inhibitor, rucaparib is expected to be more effective in the 9% of pancreatic cancers with a BRCA mutation (BRCA1 or BRCA2). [7]